Outlook Therapeutics is a small biopharmaceutical company focused on a single product: LYTENAVA (ONS-5010), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD). Bevacizumab is an anti-VEGF antibody widely used off-label for wet AMD for years, but LYTENAVA is the first formally approved ophthalmic formulation of the drug. Outlook sells LYTENAVA directly to retinal physicians, hospitals, and clinics, with Cencora handling distribution and market access support in the EU and UK. LYTENAVA has received marketing authorization in the EU and UK, with commercial launches in Germany and the UK beginning in mid-2025. In the U.S., the FDA is reviewing Outlook's resubmitted BLA, though approval remains uncertain after the primary endpoint was not met in the NORSE EIGHT trial. Outlook's pricing strategy positions LYTENAVA below branded anti-VEGF therapies but above off-label compounded bevacizumab, targeting physicians and health systems seeking a cost-effective, on-label alternative. Outlook outsources all manufacturing to contract manufacturers, making its cost structure largely variable. The company is pre-revenue and cash-burning as it funds European commercialization and pursues U.S. approval. Beyond wet AMD, Outlook holds FDA-agreed protocols for trials in diabetic macular edema and branch retinal vein occlusion, though these trials have not yet started. Greater China rights are licensed royalty-free to a joint venture with Syntone.